Cathie Wood’s ARK Invest Dumps Rocket Lab (RKLB) While Loading Up on Intellia Therapeutics

Key Takeaways

• ARK Invest liquidated 50,312 Rocket Lab shares valued at approximately $4 million via its ARKQ fund on April 27
• The sale marks the second divestment in less than a week, following Friday’s disposal of over 113,000 shares
• The investment firm accumulated 263,848 Intellia Therapeutics shares totaling roughly $3.6 million through ARKK and ARKG funds
• Additionally, ARK divested 13,806 Iridium Communications shares valued at approximately $538,000
• Rocket Lab stock advanced 3.28% on Monday, finishing at $82.29 despite ARK’s continued selling

Cathie Wood’s investment management firm, ARK Invest, executed multiple strategic portfolio adjustments on Monday, April 27, 2026, as revealed in the company’s routine daily trading disclosures.

The most significant transaction involved divesting 50,312 shares of Rocket Lab through the ARKQ exchange-traded fund, representing approximately $4.01 million in value. This divestment occurred merely days following ARK’s disposal of more than 113,000 shares of the aerospace company on the preceding Friday.

Rocket Lab USA, Inc., RKLB

The consecutive sales within such a compressed timeframe indicate ARK is methodically reducing its exposure to the space launch provider.

What’s particularly noteworthy is that Rocket Lab’s stock actually gained 3.28% during Monday’s trading session, settling at $82.29. This indicates ARK capitalized on upward momentum rather than panic-selling during a decline.

The firm seems to be capturing gains in anticipation of Rocket Lab’s quarterly financial results for the first quarter of 2026, slated for release on May 7, 2026.

Financial analysts on Wall Street anticipate Rocket Lab will announce quarterly revenues of $189.65 million, representing a 55% year-over-year increase. They also forecast an earnings loss of $0.07 per share, showing improvement compared to the $0.12 per share loss reported during the corresponding period in 2025.

ARK Accumulates Intellia Therapeutics Shares

While reducing its Rocket Lab holdings, ARK aggressively purchased Intellia Therapeutics stock. The firm acquired 263,848 shares distributed between its ARKK and ARKG exchange-traded funds, representing approximately $3.6 million in total value.

Intellia specializes in gene-editing technology, and its shares declined 4.33% during Monday’s session. ARK apparently capitalized on this price weakness as an attractive entry point.

This buying behavior aligns with ARK’s established investment approach, which frequently involves increasing positions during temporary selloffs in companies the firm believes have significant long-term growth potential.

ARK additionally disposed of 13,806 shares of Iridium Communications through its ARKX fund, totaling roughly $538,000. This sale continues an ongoing divestment pattern — ARK sold 33,315 Iridium shares during the previous Friday’s trading and 81,422 shares on the Monday prior.

Wall Street Perspective on Rocket Lab

Despite ARK’s continued selling activity, at least one prominent Wall Street analyst maintains an optimistic outlook on Rocket Lab.

Stifel analyst Erik Rasmussen elevated his price objective for the stock to $105 from $90 while maintaining a Buy recommendation. He pointed to consistent revenue expansion, a robust pipeline of contracted projects, and the anticipated debut of the Neutron rocket system later in 2026.

According to TipRanks data, Rocket Lab currently maintains a Moderate Buy consensus among analysts, supported by nine Buy recommendations and four Hold ratings issued within the last three months.

The consensus price target among analysts stands at $89.00, suggesting potential upside of approximately 8% from current trading levels.

ARK’s subsequent daily trading report will reveal whether the investment firm continued trimming its Rocket Lab stake during Tuesday’s session.

The post Cathie Wood’s ARK Invest Dumps Rocket Lab (RKLB) While Loading Up on Intellia Therapeutics appeared first on Blockonomi.